ADVM

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Adverum Biotechnologies Inc

NASDAQ | ADVM

4.12

USD

$0.00

(

0.00%

)

At Close (As of Nov 28, 2025)

$91.84M

Market Cap

-

P/E Ratio

-8.56

EPS

$6.98

52 Week High

$1.78

52 Week Low

HEALTHCARE

Sector

ADVM Chart

Recent Chart
Price Action

ADVM Technicals

Tags:

ADVM Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1M
Total Revenue $1M
Cost Of Revenue $3.7M
Costof Goods And Services Sold $3.7M
Operating Income -$139M
Selling General And Administrative $63M
Research And Development $77M
Operating Expenses $140M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.7M
Income Before Tax -$131M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$131M
Comprehensive Income Net Of Tax -
Ebit -$139M
Ebitda -$136M
Net Income -$131M

Revenue & Profitability

Earnings Performance

ADVM Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $180M
Total Current Assets $131M
Cash And Cash Equivalents At Carrying Value $61M
Cash And Short Term Investments $61M
Inventory -
Current Net Receivables -
Total Non Current Assets $49M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $65M
Other Current Assets $5.6M
Other Non Current Assets -
Total Liabilities $109M
Total Current Liabilities $23M
Current Accounts Payable $1.6M
Deferred Revenue -
Current Debt -
Short Term Debt $5.7M
Total Non Current Liabilities $86M
Capital Lease Obligations $92M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $92M
Other Current Liabilities $15M
Other Non Current Liabilities $192K
Total Shareholder Equity $71M
Treasury Stock -
Retained Earnings -$1.1B
Common Stock $2K
Common Stock Shares Outstanding $20M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$92M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $3.7M
Capital Expenditures $388K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$42M
Cashflow From Financing $120M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$131M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1M
Total Revenue $1M
Cost Of Revenue $3.7M
Costof Goods And Services Sold $3.7M
Operating Income -$139M
Selling General And Administrative $63M
Research And Development $77M
Operating Expenses $140M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.7M
Income Before Tax -$131M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$131M
Comprehensive Income Net Of Tax -
Ebit -$139M
Ebitda -$136M
Net Income -$131M

ADVM News

ADVM Profile

Adverum Biotechnologies Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company headquartered in Redwood City, California, dedicated to developing transformative therapeutic solutions for rare diseases and ophthalmic disorders. The company boasts a promising pipeline of gene therapy candidates that harness its proprietary adeno-associated virus (AAV) technologies, aiming to meet substantial unmet medical needs. By focusing on innovative treatments, Adverum is strategically positioned to enhance patient outcomes and solidify its presence within the rapidly advancing gene therapy landscape.

LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
AMZE
+21.21%
$0.48
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.91%
$7.68
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
INHD
-0.99%
$0.22
ADD
-25.47%
$0.05
CHR
-3.48%
$0.04
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
BMNU
+8.84%
$8.18
ONMD
+30.28%
$1.85
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
VALE
+0.79%
$12.61
SOFI
+4.31%
$29.72
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
ADTX
+21.01%
$3.80
DEFT
+9.35%
$1.52
BTG
+3.35%
$4.62
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.00%
$7.79
AFMD
-34.94%
$0.18
PFE
+0.11%
$25.74
CAN
+0.75%
$0.92
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
0.00%
$2.56
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
NWTN
-9.09%
$0.70
AIIO
-9.09%
$0.70
AG
+12.73%
$15.23
WBD
+0.50%
$24.00
VEEE
+45.50%
$2.59
APLD
+8.66%
$27.10
GOOG
-0.05%
$320.12
NGD
+6.50%
$8.35
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
CDE
+6.67%
$17.27
PLTR
+1.61%
$168.45
ITUB
+1.82%
$7.80
CRCA
+19.56%
$4.40
AGNC
+0.47%
$10.49
T
+0.77%
$26.02
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
BTE
+1.89%
$3.22
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12
LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
AMZE
+21.21%
$0.48
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.91%
$7.68
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
INHD
-0.99%
$0.22
ADD
-25.47%
$0.05
CHR
-3.48%
$0.04
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
BMNU
+8.84%
$8.18
ONMD
+30.28%
$1.85
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
VALE
+0.79%
$12.61
SOFI
+4.31%
$29.72
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
ADTX
+21.01%
$3.80
DEFT
+9.35%
$1.52
BTG
+3.35%
$4.62
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.00%
$7.79
AFMD
-34.94%
$0.18
PFE
+0.11%
$25.74
CAN
+0.75%
$0.92
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
0.00%
$2.56
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
NWTN
-9.09%
$0.70
AIIO
-9.09%
$0.70
AG
+12.73%
$15.23
WBD
+0.50%
$24.00
VEEE
+45.50%
$2.59
APLD
+8.66%
$27.10
GOOG
-0.05%
$320.12
NGD
+6.50%
$8.35
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
CDE
+6.67%
$17.27
PLTR
+1.61%
$168.45
ITUB
+1.82%
$7.80
CRCA
+19.56%
$4.40
AGNC
+0.47%
$10.49
T
+0.77%
$26.02
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
BTE
+1.89%
$3.22
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.